Pascal Benkert

List of Publications by Year
in descending order

61 papers	**8,018** citations	218677 **26** h-index	123424 **61** g-index
62 all docs	**62** docs citations	**62** times ranked	**13313** citing authors

#	Article	IF	Citations
1	Toward the estimation of the absolute quality of individual protein structure models. Bioinformatics, 2011, 27, 343-350.	4.1	1,855
2	Protein structure homology modeling using SWISS-MODEL workspace. Nature Protocols, 2009, 4, 1-13.	12.0	1,092
3	QMEAN: A comprehensive scoring function for model quality assessment. Proteins: Structure, Function and Bioinformatics, 2008, 71, 261-277.	2.6	888
4	Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Annals of Neurology, 2017, 81, 857-870.	5.3	768
5	QMEAN server for protein model quality estimation. Nucleic Acids Research, 2009, 37, W510-W514.	14.5	716
6	Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain, 2018, 141, 2382-2391.	7.6	345
7	Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nature Communications, 2020, 11, 812.	12.8	316
8	Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurology, The, 2022, 21, 246-257.	10.2	210
9	Comparison of ^{68}Ga-DOTANOC and ^{68}Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine, 2013, 54, 364-372.	5.0	184
10	Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 73, 989-999.	2.8	148
11	QMEANclust: estimation of protein model quality by combining a composite scoring function with structural density information. BMC Structural Biology, 2009, 9, 35.	2.3	131
12	Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurology, 2019, 76, 1359.	9.0	129
13	Prodromal symptoms of multiple sclerosis in primary care. Annals of Neurology, 2018, 83, 1162-1173.	5.3	98
14	Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology, 2020, 94, e1201-e1212.	1.1	88
15	Heart Failure Therapy–Induced Early ST2 Changes May Offer Long-Term Therapy Guidance. Journal of Cardiac Failure, 2013, 19, 821-828.	1.7	69
16	Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019. Annals of Neurology, 2021, 89, 610-616.	5.3	68
17	Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology, 2020, 94, e2457-e2467.	1.1	61
18	Global and local model quality estimation at CASP8 using the scoring functions QMEAN and QMEANclust. Proteins: Structure, Function and Bioinformatics, 2009, 77, 173-180.	2.6	56

#	Article	IF	Citations
19	Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis. Neurology, 2021, 97, e543-e553.	1.1	54
20	Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 777-785.	3.0	46
21	Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Journal of Neuroinflammation, 2021, 18, 105.	7.2	44
22	Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	43
23	Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurology, 2022, 79, 682.	9.0	41
24	The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS ONE, 2016, 11, e0152347.	2.5	38
25	Factors influencing serum neurofilament light chain levels in normal aging. Aging, 2021, 13, 25729-25738.	3.1	38
26	Temporal association of sNfL and gad–enhancing lesions in multiple sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 945-955.	3.7	35
27	Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	32
28	Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	29
29	Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	24
30	Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population–an analysis from the MEMO study. BMC Medicine, 2021, 19, 38.	5.5	24
31	Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. Brain Communications, 2020, 2, fcaa166.	3.3	24
32	Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma. World Journal of Gastroenterology, 2014, 20, 4994.	3.3	24
33	Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment. European Journal of Neurology, 2020, 27, 1066-1075.	3.3	21
34	Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. Neurology, 2021, 97, e1466-e1474.	1.1	20
35	Development of an age–adjusted model for blood neurofilament light chain. Annals of Clinical and Translational Neurology, 2022, 9, 444-453.	3.7	19
36	Sustained reduction of serum neurofilament light chain over 7‰years by alemtuzumab in early relapsing–remitting MS. Multiple Sclerosis Journal, 2022, 28, 573-582.	3.0	17

#	Article	IF	Citations
37	Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis. Journal of Neurology, 2021, 268, 941-949.	3.6	16
38	Serum neurofilament measurement improves clinical risk scores for outcome prediction after cardiac arrest: results of a prospective study. Critical Care, 2021, 25, 32.	5.8	16
39	Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. Annals of Neurology, 2021, 90, 477-489.	5.3	16
40	Renal Function and Body Mass Index Contribute to Serum Neurofilament Light Chain Levels in Elderly Patients With Atrial Fibrillation. Frontiers in Neuroscience, 2022, 16, 819010.	2.8	15
41	Generating evidence on a risk-based monitoring approach in the academic setting – lessons learned. BMC Medical Research Methodology, 2017, 17, 26.	3.1	14
42	Accurate classification of secondary progression in multiple sclerosis using a decision tree. Multiple Sclerosis Journal, 2021, 27, 1240-1249.	3.0	14
43	Very Low Hepatitis C Viral Loads in Treatment-naive Persons: Do They Compromise Hepatitis C Virus Antigen Testing?. Clinical Infectious Diseases, 2019, 70, 653-659.	5.8	13
44	Uncertainties about the need for ethics approval in Switzerland: a mixed-methods study. Swiss Medical Weekly, 2020, 150, w20318.	1.6	13
45	Validity of mobile electronic data capture in clinical studies: a pilot study in a pediatric population. BMC Medical Research Methodology, 2017, 17, 163.	3.1	11
46	Improving your target-template alignment with MODalign. Bioinformatics, 2012, 28, 1038-1039.	4.1	10
47	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. Multiple Sclerosis Journal, 2022, 28, 71-81.	3.0	10
48	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2001-2013.	3.0	9
49	Refinement of unbound protein docking studies using biological knowledge. Proteins: Structure, Function and Bioinformatics, 2005, 61, 1059-1067.	2.6	8
50	Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate. Multiple Sclerosis Journal, 2021, 27, 439-448.	3.0	8
51	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 388-393.	2.0	8
52	Immunological Predictors of Dimethyl Fumarate–Induced Lymphopenia. Annals of Neurology, 2022, 91, 676-681.	5.3	8
53	Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation. Heart Rhythm, 2021, 18, 512-519.	0.7	7
54	Intrathecal IgM Synthesis Is Associated with Spinal Cord Manifestation and Neuronal Injury in Early MS. Annals of Neurology, 2022, 91, 814-820.	5.3	7

#	ARTICLE	IF	CITATIONS
55	Monitoring strategies for clinical intervention studies. The Cochrane Library, 2022, 2022, MR000051.	2.8	5
56	Diagnosis and treatment of iron deficiency in medical inpatients at a Swiss tertiary university referral hospital: a retrospective observational cohort study of clinical practice. Swiss Medical Weekly, 2013, 143, w13847.	1.6	4
57	Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis. Diagnostic and Prognostic Research, 2021, 5, 17.	1.8	4
58	Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person‐centred approach. Journal of Viral Hepatitis, 2016, 23, 697-707.	2.0	3
59	Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies. Frontiers in Neuroscience, 2021, 15, 791670.	2.8	2
60	Monitoring strategies for clinical intervention studies. The Cochrane Library, 2019, , .	2.8	1
61	Antibodies to neurofilament light as potential biomarkers in multiple sclerosis. BMJ Neurology Open, 2021, 3, e000192.	1.6	1